Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Blokhin's Russian Cancer Research Center
Hoffmann-La Roche
UMC Utrecht
Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center
Neonc Technologies, Inc.
Jonsson Comprehensive Cancer Center
Iambic Therapeutics, Inc
Adela, Inc
Mayo Clinic
University of Southern California
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
AVM Biotechnology Inc
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Poitiers University Hospital
National Cancer Institute (NCI)
Apollomics Inc.
NRG Oncology
Mayo Clinic
Columbia University
Tempus AI
University of South Florida
Cedars-Sinai Medical Center
University of Michigan Rogel Cancer Center
ABM Therapeutics Corporation
VitaMed Research LLC
Dana-Farber Cancer Institute
Washington University School of Medicine
Wake Forest University Health Sciences
Mayo Clinic
University of Sydney
Universitaire Ziekenhuizen KU Leuven
Second Affiliated Hospital of Guangzhou Medical University
University of Southern California
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
University of Florida
Kaohsiung Medical University Chung-Ho Memorial Hospital
Mayo Clinic
Aarhus University Hospital
Quadriga Biosciences, Inc.
Health Clinics Limited
Albert Einstein College of Medicine
SpeciCare
University Hospital Tuebingen
Chinese PLA General Hospital